Literature DB >> 19716944

Phosphodiesterase-4 inhibition in COPD.

Paul M O'Byrne1, Gail Gauvreau.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19716944     DOI： 10.1016/S0140-6736(09)61538-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  [Phosphodiesterase 4 inhibition for treatment of endothelial barrier and microcirculation disorders in sepsis].

Authors:  J Wollborn; N Schlegel; M A Schick
Journal:  Anaesthesist       Date:  2017-05       Impact factor: 1.041

2.  Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway.

Authors:  Jiyun Lee; Kensei Komatsu; Byung Cheol Lee; Jae Hyang Lim; Hirofumi Jono; Haidong Xu; Hirofumi Kai; Z John Zhang; Chen Yan; Jian-Dong Li
Journal:  J Biol Chem       Date:  2012-05-18       Impact factor: 5.157

3.  Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma.

Authors:  Nicolas Dumaz
Journal:  Small GTPases       Date:  2011-09-01

4.  ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.

Authors:  Amélie Marquette; Jocelyne André; Martine Bagot; Armand Bensussan; Nicolas Dumaz
Journal:  Nat Struct Mol Biol       Date:  2011-04-10       Impact factor: 15.369

5.  PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.

Authors:  Sabrina Noel; Barbara Dhooghe; Teresinha Leal
Journal:  Front Pharmacol       Date:  2012-09-18       Impact factor: 5.810

6.  Molecular targeted therapies in metastatic melanoma.

Authors:  Rima Chakraborty; Carilyn N Wieland; Nneka I Comfere
Journal:  Pharmgenomics Pers Med       Date:  2013-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.